Melanotan II: What the Evidence Actually Shows

Search "Melanotan II" and it's usually pitched as an injectable sunless tan with a libido bonus, often name-dropped alongside PT-141 as if the two are interchangeable. They aren't, and Melanotan II is an unusual case in this article series for a different reason too: unlike most peptides sold in this market, it began life as an actual pharmaceutical candidate, with real early-phase human trials behind it. That's not automatically reassuring. This article traces what those trials actually found, how Melanotan II relates to PT-141, and — the part most product pages skip — the real, published, and still-growing case-report record of harm from its unregulated use.

What Melanotan II actually is, and how it relates to PT-141

Melanotan II (MT-II) is a synthetic, lactam-bridged cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) — its own published structure is Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-alpha-MSH(4-10)-NH2 — and a non-selective agonist active across several melanocortin receptors¹. It was developed in the late 1980s and early 1990s at the University of Arizona by a research group (Hadley, Hruby, Dorr, Levine, and colleagues) that also developed a related but chemically distinct linear analog, [Nle4,D-Phe7]-alpha-MSH — commonly called Melanotan-I or NDP-alpha-MSH — tested in a separate, larger human trial covered below²³. The two are not the same molecule sold under two names: Melanotan-I is linear, Melanotan II is cyclic, and they have separate, if overlapping, research and case-report literatures.

Melanotan II is also the direct structural parent of PT-141 (bremelanotide), the FDA-approved active ingredient in Vyleesi, already covered in depth in PeptideRank's own PT-141 evidence review. A 2006 review co-authored by one of the original University of Arizona MT-II researchers states the relationship directly, describing PT-141 as "a new MTII analog" developed by Palatin Technologies² — meaning PT-141 wasn't independently discovered and later found to resemble Melanotan II; it was engineered from Melanotan II's own molecular scaffold, specifically trading away the pigmentation effect for more selective activity at MC4R. Melanotan II's own clinical testing, covered next, is the direct research lineage that eventually produced Vyleesi — but Melanotan II itself was never advanced to FDA approval and remains, today, a separate, unapproved compound from both Melanotan-I and PT-141.

What the evidence actually shows for tanning

Unlike most peptides PeptideRank has reviewed in this series, Melanotan II does have real, published human trial data behind its primary marketed use — because it was originally developed as a pharmaceutical candidate, not first sold as a research chemical. The key early study is a 1996 pilot Phase I trial: three healthy male volunteers received escalating low subcutaneous doses of MT-II (starting at 0.01 mg/kg), roughly every other day for two weeks, in a single-blind, placebo-alternating design. Two of the three subjects showed measurably increased pigmentation in the face, upper body, and buttocks a week after dosing ended, by both quantitative reflectance and visual assessment — confirming tanning activity in humans at low doses¹. That same small trial is also the first place spontaneous erections and nausea show up in the literature, at higher doses, discussed further below.

A larger, controlled human tanning trial exists too, but it's important not to conflate it with Melanotan II specifically: a 1991 randomized, double-blind, placebo-controlled JAMA trial in 28 healthy men found that repeated subcutaneous injections of a synthetic melanotropin produced significant, dose-related skin darkening, with no darkening in the placebo group³ — genuinely strong human evidence for the tanning mechanism this whole drug family relies on. But the compound tested there was NDP-alpha-MSH — Melanotan-I, the linear analog — not the cyclic Melanotan II product sold online today. It's directly relevant background (same research group, same melanogenesis pathway) but not itself MT-II human data.

Melanotan II was never carried past early-phase human testing as a tanning drug in its own right. Its clinical development shifted almost entirely toward erectile dysfunction after the Phase I trial above turned up spontaneous erections as a side effect: a 1998 double-blind, placebo-controlled crossover trial in 10 men with psychogenic erectile dysfunction found MT-II produced clinically apparent erections in 8 of 10 men, with significantly longer measured rigidity than placebo⁴, and a follow-up analysis pooling 20 men found erections in 17 of 20 and increased self-reported sexual desire after 68% of MT-II doses versus 19% of placebo doses⁵. That pivot is also why Melanotan II itself was never pursued to an FDA submission: the university researchers' own patented follow-on compound for that indication became PT-141, not MT-II.

Documented safety concerns

Because Melanotan II never went through full-scale drug development, there's no large Phase 3 safety database behind it. What exists instead is the small early trials above, plus a substantial and growing published case-report literature from its unregulated, internet-sourced use since the 2000s — most of it from dermatology, toxicology, and emergency-medicine journals.

The most consistently reported concern is melanocytic: multiple independent case reports describe new ("eruptive") moles or darkening and shape changes in pre-existing moles appearing within hours to days of a Melanotan II injection⁶⁷. A 2017 review of the unregulated alpha-MSH-analog market found this pattern common enough to be a recurring theme across case reports, and more seriously, identified four separate published case reports in which melanoma was diagnosed emerging from an existing mole either during or shortly after Melanotan use — while adding directly that "conclusive evidence linking these phenomena is lacking"⁶. That caveat matters and shouldn't be dropped: a temporal association across four case reports is a real safety signal worth taking seriously, not proof of causation, since people already prone to changing moles may also be more likely to seek out a tanning product in the first place. The same review notes, for contrast, that afamelanotide (marketed as Scenesse) — a related but chemically distinct alpha-MSH analog — is "the only α-MSH analogue that is approved for use," and has been "thoroughly tested and deemed safe" for its own narrow set of approved indications; Melanotan II has never gone through anything comparable⁶. The safety signal has continued into recent literature: a 2025 case report describes a mucosal melanoma of the jaw in a 22-year-old woman who had used intranasal Melanotan II for tanning¹².

Separate from the melanocytic signal, acute cardiovascular and systemic toxicity has been directly documented at higher-than-recommended doses. A 2012 case report describes a man who injected six times his stated starting dose and presented two hours later with tachycardia (heart rate up to 146 bpm), elevated blood pressure, agitation, and rhabdomyolysis, with creatine kinase peaking near 17,800 IU/L and acute kidney injury requiring three days of ICU care⁸. A 2013 case report describes posterior reversible encephalopathy syndrome — a rare, serious brain condition classically triggered by acute severe hypertension — following Melanotan use⁹. Separately, case reports describe acute ischemic priapism requiring emergency urological intervention after Melanotan II injection¹⁰, and a case report describes a probable renal infarction attributed to the drug¹¹ — both plausible extensions of the same vascular/smooth-muscle mechanism that gives Melanotan II its erectile effect in the first place, here showing up as a documented harm rather than an intended one.

The current FDA and compounding status

Melanotan II has never had an FDA-approved drug product. A direct, live check against DailyMed returns zero results for "melanotan" in any form. Unlike its structural offspring PT-141/bremelanotide (approved as Vyleesi in 2019) and unlike afamelanotide, the chemically distinct alpha-MSH analog approved as Scenesse for a narrow set of light-sensitivity conditions⁶, Melanotan II itself has never been the active ingredient in any FDA-approved product.

Its compounding status tracks the same twelve-peptide FDA action that moved BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and DSIP/Emideltide: it sat on FDA's interim Section 503A Category 2 bulk-substances list — significant safety risk, should not be compounded — from 2023 until FDA removed it on April 15, 2026 (effective April 22), because the nomination behind that listing was withdrawn. That is a procedural change, not a safety finding, and does not make compounding it legal.

Unlike the seven peptides FDA's advisory committee already voted on in July 2026 (including DSIP, which itself failed its vote — see PeptideRank's DSIP evidence review), Melanotan II was not part of that hearing at all. A regulatory summary of the same April 2026 Category 2 removal confirms FDA's committee will instead take up Melanotan II — together with injectable GHK-Cu, DiHexa, cathelicidin LL-37, and PEG-MGF — at a separate meeting scheduled before the end of February 2027¹³. As of this review, that meeting has not happened. Melanotan II's compounding review is therefore a full step further from resolution than DSIP's, KPV's, or any of the six recommended peptides: it hasn't had its committee hearing at all yet, so there's no vote outcome — good or bad — to report.

What this means if you're considering a compounded Melanotan II product

Melanotan II is a genuinely unusual case in this article series: real human trial data exists for its central marketed use, because it began life as an actual pharmaceutical candidate rather than a research chemical repurposed for the supplement market. Two of three subjects tanned in its own small Phase I trial, and a related linear compound produced strong, statistically clear tanning in a much larger placebo-controlled trial. That's more direct human evidence than several other peptides on this site have for their own marketed uses.

What sits on the other side of that ledger is a real, published, and still-growing case-report record of harm: eruptive and changing moles, four case reports of melanoma temporally associated with use (with the caveat that causation isn't established), documented cardiovascular toxicity and rhabdomyolysis at above-label doses, a case of posterior reversible encephalopathy syndrome, and cases of priapism and renal infarction. Unlike DSIP or KPV, where the honest problem is an absence of human evidence, Melanotan II's honest problem is closer to the opposite: there's real evidence it does something physiologically substantial in a living person, and real, independently reported evidence that "something substantial" has, repeatedly, gone wrong — from a bad night in an emergency room to a melanoma diagnosis. That combination, plus a compounding review that hasn't even started, is worth weighing carefully against any product page's tanning or libido claims. Our Melanotan II reconstitution calculator covers the current compounding-status caution in more detail and does the vial-to-syringe arithmetic; it doesn't, and can't, weigh that safety record for you.